Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/9/2025

Autoimmune Hepatitis Diagnosis and Treatment

Diagnosis

  • The American Association for the Study of Liver Diseases recommends a systematic diagnostic approach combining clinical, serological, and histological criteria before initiating treatment for autoimmune hepatitis (AIH) 1
  • A comprehensive history focusing on medication exposure, alcohol intake, viral hepatitis exposure, and family history of autoimmune diseases is essential for diagnosis 1
  • A complete "non-invasive" liver screen to exclude viral hepatitis and metabolic liver diseases is necessary 1
  • Measuring serum autoantibodies, including ANA, SMA, or LKM-1, and quantifying IgG and globulin levels is crucial for diagnosis 1
  • Liver biopsy is essential for diagnosis and provides critical prognostic information, unless active contraindications exist 1
  • The revised IAIHG scoring system should be applied when diagnosis is uncertain, with a definite AIH score >15 and probable AIH score 10-15 1

Treatment

  • The European Association for the Study of the Liver recommends immediate immunosuppressive therapy for patients with severe disease manifestations, with a mortality rate of 60% at 6 months if untreated 2
  • Patients with serum AST/ALT >10-fold upper limit of normal (ULN) or ≥5-fold ULN with serum globulin ≥2-fold ULN require immediate treatment 1, 2
  • Histological findings of bridging necrosis or multilobular necrosis indicate severe disease and require immediate treatment, with an 82% progression to cirrhosis if untreated 2
  • The standard first-line treatment is prednisolone plus azathioprine, achieving remission in 80-90% of patients with significantly improved survival 3, 4
  • The American College of Gastroenterology recommends a prednisolone dose of 30 mg/day initially, reducing to 10 mg/day over 4 weeks, and an azathioprine dose of 1 mg/kg/day 5, 3

Treatment Monitoring and Adjustment

  • The therapeutic endpoint is complete normalization of serum AST, ALT, and IgG levels, with persistent elevation of liver enzymes predicting relapse after treatment withdrawal 6, 3, 4
  • Patients with normalized labs before drug withdrawal have a 3-11 fold lower relapse risk compared to those who don't achieve this endpoint 6
  • Clinical and laboratory improvement occurs within 2-4 weeks in most patients, with biochemical remission typically achieved within 6-12 months 6, 4
  • Histological resolution lags behind biochemical improvement by 3-8 months, and average treatment duration is 18-24 months before considering withdrawal 6

Special Clinical Situations

  • Acute severe AIH or fulminant hepatic failure requires high-dose intravenous corticosteroids as early as possible, with contact of a liver transplant center immediately for patients with liver failure or bridging necrosis 3, 4, 5, 7
  • AIH-PBC overlap syndrome requires combined therapy with ursodeoxycholic acid (UDCA) plus immunosuppressants, with UDCA dosing at 13-15 mg/kg/day 7, 4
  • Pregnancy considerations include risk-benefit analysis for azathioprine, which may be continued if disease control requires it, while MMF is absolutely contraindicated in pregnancy 4, 8
  • Children with AIH require treatment indications similar to adults, with high-dose prednisone for up to 2 weeks, then gradual decrease to maintenance, and 80-90% achieving laboratory remission in 6-12 months 2, 6

Treatment of Asymptomatic Autoimmune Hepatitis

Introduction to Treatment

  • The American Association for the Study of Liver Diseases recommends treating asymptomatic patients with autoimmune hepatitis using immunosuppressive therapy, as untreated patients have significantly lower 10-year survival rates (67% versus 98%) 9

When to Treat Asymptomatic Patients

  • Asymptomatic patients with AST or ALT >10-fold upper limit of normal (ULN) should be treated immediately, as should those with AST or ALT ≥5-fold ULN and serum globulin ≥2-fold ULN, or histological findings of bridging necrosis or multilobular necrosis 9
  • Untreated asymptomatic patients with mild disease have lower 10-year survival rates than treated counterparts (67% versus 98%), and spontaneous improvement occurs in only 12% of untreated asymptomatic patients versus 63% of treated patients 9
  • Mild autoimmune hepatitis can progress despite lack of symptoms, and young patients are particularly favored for treatment to prevent cirrhosis development over decades 9, 10
  • Patients with established cirrhosis on biopsy should be treated due to adverse prognostic features 10

Treatment Regimen

  • The recommended treatment regimen is combination therapy with prednisolone (30 mg/day initially, tapering to 10 mg/day maintenance) plus azathioprine (1-2 mg/kg/day), which achieves remission in 80-90% of patients 11

Critical Safety Considerations

  • Before starting azathioprine, check thiopurine methyltransferase (TPMT) levels to exclude homozygote deficiency, especially in patients with pre-existing leucopenia, and do not start azathioprine if white blood cell count <2.5 × 10⁹/L or platelets <50 × 10⁹/L 9, 11
  • Do not treat patients with serious pre-existing comorbid conditions (e.g. vertebral compression, psychosis, brittle diabetes, uncontrolled hypertension) or previous prednisone intolerance unless disease is severe and progressive 9, 11